VolitionRx Delivers a Business Update and Appoints Vital Officers to Drive Commercialization Efforts

AUSTIN, Texas, Feb. 2, 2021 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) these days supplied a company update and introduced the appointment of a new Main Economic Officer, Mr. Terig Hughes, in addition to the appointment of Dr. Gaetan Michel as Chief Working Officer, Mr. Gael Forterre as Main Industrial Officer, and Dr. Mark Eccleston as Main Technology Officer.

“Inspite of the pandemic we accomplished a good deal throughout 2020 and the momentum has ongoing into 2021 with a really active January. We have opened our new production facility “Silver Just one”, introduced more non-dilutive funding of about $4 million and introduced the to start with info from our significant-scale lung most cancers review,” commented Cameron Reynolds, President and Group Chief Govt Officer. “As we changeover from a investigate and progress corporation to a industrial firm, we are delighted to fortify the management staff with the appointment of Terig and Gael and the nicely-deserved promotions of Gaetan and Mark. All 4 bring solid world-wide experience and expertise to their respective roles and these appointments aim to supply a really sturdy product or service aim to our administration staff. Make sure you take a couple of minutes to check out the video clip below for a corporation update and to fulfill the new members of our management staff.”

Mr. Reynolds extra, “We would also like to thank Mr. David Vanston, our former Chief Financial Officer, for his contributions to Volition all through his tenure with us and we want him nicely in his long term endeavors.”

Look at a online video offering a organization update and introducing Volition’s new team members in this article – https://youtu.be/JznLeU0UOtg

Mr. Hughes, our new Chief Financial Officer, is a seasoned finance skilled with about twenty-five several years of accounting, finance and enterprise administration practical experience received by an worldwide job spanning the United States, Europe and Asia and joins Volition from AUM Biosciences Pte. Ltd., a rapidly-growing biotechnology organization concentrated on building novel most cancers medications, where he acted as Main Economical Officer considering the fact that 2018. Prior to then, Mr. Hughes held a variety of senior management positions at Elsevier, a division of RELX Group plc, a FTSE 100 company, like regional Running Director and regional Finance Director for Elsevier Health and fitness Alternatives. He has extensive practical experience in economic reporting, planning & assessment, and earnings and decline administration, as effectively as product or service commercialization, licensing and distributor management.

Mr. Hughes holds a Bachelor’s degree in Accounting and Legislation from De Montfort College, Leicester, United kingdom.

Commenting on his appointment Mr. Hughes explained, “I am delighted to sign up for Volition at this fascinating time, not only will product launches aid saves lives as a result of earlier analysis they must also enable deliver lengthy phrase benefit for our stockholders.”

Mr. Gael Forterre, our new Main Business Officer, has above 15 many years of working experience investing in and scaling speedy developing businesses. Mr. Forterre began his career as a hedge fund analyst in Paris and worked in a selection of investment decision banking and trading roles around ten plus several years, together with launching Armori Cash Management LLC in 2014, for which he done a big range of investments on behalf of relatives workplaces/institutional investors and turned energetic in supporting the progress of its portfolio providers. Most recently, from 2017 until finally joining Volition, he served as the Chief Govt Officer of Ucroo Included, a speedy-expanding collaboration and interaction engineering company, which he led to a tripling in earnings progress two yrs in a row. Mr. Forterre carries on to serve as a board member of Ucroo Incorporated and Posting22.

Mr. Forterre retains a Master’s diploma in finance from Sorbonne Paris I and a double MBA from Columbia Business enterprise School and the London Organization Faculty.

“Just after far more than 15 several years of investing and encouraging companies scale, I come across Volition to have the most persuasive prospective,” commented Mr. Forterre, “and am delighted to sign up for the passionate group to push commercialization of the products pipeline.”

Mr. Forterre will emphasis on building a sturdy commercialization system and group to drive the in depth variety of products to be created making use of the Nu.Q™ system.

Dr. Gaetan Michel, our new Chief Functioning Officer, has been with Volition virtually seven decades, previously serving as Chief Working Officer of Belgian Volition and at the moment as Chief Govt Officer of Belgian Volition. With around 15 years of job management, manufacturing and operational knowledge, Dr. Michel is preferably placed to oversee and expand Volition’s international functions including the recently opened Innovation Hub in San Diego, the manufacturing facility “Silver A person” and Investigation and Progress Facility in Belgium, as perfectly as increasing the veterinary subsidiary in Texas, U.S.A.

“I am honored to take the placement of Main Running Officer of Volition,” commented Dr. Michel, ” and glance ahead to executing our enlargement strategies all over 2021 and outside of as we roll out our Nu.Q™ system around the world.”

Dr. Mark Eccleston, a person of Volition’s founding experts will now serve as our new Chief Technological innovation Officer. Dr. Eccleston has above 20 years’ expertise in the biotechnology sector and holds a PhD in Polymer Chemistry for biomedical programs. In this new function, he will determine and critique new and ground breaking infrastructures which will aid in the deployment of Volition’s proprietary Nu.Q™ platform.

“Right after 10 yrs with Volition it is however tremendously gratifying doing the job on these a cutting-edge technology,” commented Dr. Eccleston, “Nu.Q™ not only has the potential to assistance diagnose most cancers, but potentially quite a few other serious problems. I look ahead to this new purpose the place I can engage in a important element in analysis and sourcing the technology platforms that can support with a assortment of Nu.Q™ solution launches.”

For even further aspects remember to contact [email protected].

About Volition

Volition is a multi-countrywide epigenetics company developing straightforward, simple to use, price tag efficient blood tests to support diagnose a range of cancers and other health conditions. Early diagnosis has the opportunity to not only lengthen the existence of sufferers, but also to enhance their top quality of existence. The tests are dependent on the science of NucleosomicsTM, which is the observe of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indicator that disorder is existing. Volition is mostly focused on human diagnostics but also has a subsidiary concentrated on animal diagnostics.

Volition’s investigation and growth activities are centered in Belgium, with a small laboratory in California and added offices in Texas, London and Singapore, as the enterprise focuses on bringing its diagnostic items to current market.

For extra details about Volition, stop by Volition’s internet site volition.com or hook up with us by means of:

Twitter: https://twitter.com/volitionrx

LinkedIn: https://www.linkedin.com/company/volitionrx

Fb: https://www.fb.com/VolitionRx/

YouTube: https://www.youtube.com/person/VolitionRx

The contents uncovered at Volition’s site deal with, Twitter, LinkedIn, Facebook, and YouTube are not integrated by reference into this doc and should not be considered part of this doc. The addresses for Volition’s site, Twitter, LinkedIn, Fb, and YouTube are included in this doc as inactive textual references only.

Media / Trader Contacts

Secure Harbor Assertion

Statements in this press launch could be “ahead-hunting statements” in the this means of Portion 27A of the Securities Act of 1933, as amended, and Area 21E of the Securities Trade Act of 1934, as amended, that issue issues that include threats and uncertainties that could induce real benefits to differ materially from all those expected or projected in the ahead-seeking statements. Terms this sort of as “expects,” “anticipates,” “intends,” “strategies,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “prospective,” “target,” “implies,” “could,” “would,” “must,” “might,” “will” and equivalent expressions establish forward-wanting statements. These ahead-searching statements relate to the performance of Volition’s blood-primarily based diagnostic and prognostic checks, and Volition’s skill to produce and correctly commercialize these types of test platforms for early detection of cancer and other health conditions. Volition’s true outcomes might differ materially from these indicated in these forward-looking statements thanks to a lot of risks and uncertainties, including, with no limitation, outcomes of studies screening the efficacy of its exams. For occasion, if Volition fails to create and commercialize diagnostic or prognostic products and solutions, it might be unable to execute its plan of operations. Other threats and uncertainties contain Volition’s failure to get required regulatory clearances or approvals to distribute and market upcoming products and solutions a failure by the marketplace to accept the merchandise in Volition’s advancement pipeline or any other diagnostic or prognostic solutions Volition could create Volition’s failure to protected satisfactory mental house safety Volition will face fierce competitors and Volition’s intended merchandise could turn out to be obsolete thanks to the hugely competitive character of the diagnostics marketplace and its swift technological improve downturns in domestic and overseas economies and other challenges discovered in Volition’s most latest Annual Report on Type 10-K and Quarterly Studies on Sort 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are centered on present-day anticipations, estimates and projections about Volition’s enterprise primarily based, in component, on assumptions produced by management. These statements are not assures of upcoming overall performance and involve threats, uncertainties and assumptions that are tricky to predict. Forward-wanting statements are manufactured as of the day of this release, and, other than as demanded by law, Volition does not undertake an obligation to update its ahead-on the lookout statements to reflect upcoming events or circumstances.

Pursuant to the disclosure demands of the NYSE American Organization Manual Section 711(a), Volition is reporting that its Board of Administrators (which include all of its impartial directors) has approved the issuance of a warrant to buy up to 185,000 shares of Volition typical inventory (the “Warrant”) to Mr. Terig Hughes as a materials inducement for his getting into employment with Singapore Volition Pte. Constrained, Volition’s wholly-owned subsidiary, as Main Financial Officer and Treasurer. The Warrant has an exercise selling price of $4.90 for every share and is exercisable commencing February 1, 2022 (issue to (i) ongoing work by way of this sort of date, and (ii) the shares underlying the Warrant shall have been duly accredited for listing by the NYSE American prior to exercise) with an expiration date of February 1, 2027.

Nucleosomics™ and Nu.Q™ and their respective logos are emblems and/or services marks of VolitionRx Limited and its subsidiaries. All other logos, company marks and trade names referred to in this press release are the home of their respective entrepreneurs.


Check out original content material to obtain multimedia:http://www.prnewswire.com/news-releases/volitionrx-offers-a-business-update-and-appoints-essential-officers-to-travel-commercialization-endeavours-301219947.html

Supply VolitionRx Ltd

At first revealed